Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 12 mechanisms across 199 industry trials with a known mechanism of action.

See full pipeline →

Programmed Death Receptor-1 Blocking Antibody

81 trials 17 active 12 sponsors

Programmed Death Ligand-1 Blocker

27 trials 14 active 8 sponsors

Kinase Inhibitor

37 trials 13 active 16 sponsors

KRAS G12C

5 trials 3 active 2 sponsors

Dihydrofolate reductase/Folylpolyglutamate Synthetase/Glycinamide Ribonucleotide Formyltransferase/Thymidylate Synthase

23 trials 2 active 6 sponsors

Vascular Endothelial Growth Factor Inhibitor

9 trials 2 active 7 sponsors

ALK/ROS1/NTRK1/TRKB/TRKC

2 trials 2 active 1 sponsor

Vascular Endothelial Growth Factor Receptor 2 Antagonist

8 trials 1 active 1 sponsor

DNA

3 trials 1 active 3 sponsors

AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3

2 trials 1 active 2 sponsors

EGFR/ERBB2

1 trials 1 active 1 sponsor

Corticosteroid

1 trials 1 active 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

1771 industry-sponsored trials across 551 sponsors

Showing 29 of 29 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Novartis	dabrafenib	—	RECRUITING	2032-12-28	NCT03340506
Pfizer	Lorlatinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-12-28	NCT05144997
Pfizer	crizotinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2028-03-21	NCT05160922
AstraZeneca	Osimertinib+cisplatin or carboplatin + pemetrexed Edit	—	NOT YET RECRUITING	2030-05-18	NCT07279935
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2024-08-21	NCT03715205
Roche	—	—	COMPLETED	2023-11-30	NCT04180176
AstraZeneca	Durvalumab	Programmed Death Ligand-1 Blocker [EPC]	COMPLETED	2023-10-27	NCT04416633
Pfizer	Dacomitinib	DDR1/DDR2/EGFR/EPHA6/HER1/ERBB2/HER4/LCK/MNK1	COMPLETED	2022-10-15	NCT04511533
Pfizer	Lorlatinib	Kinase Inhibitor [EPC]	COMPLETED	2022-07-20	NCT04541706
Roche	Atezolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2022-04-07	NCT03285763
AstraZeneca	Osimertinib	—	COMPLETED	2020-04-15	NCT03853551
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2019-07-17	NCT03444766
Boehringer Ingelheim	Afatinib	—	COMPLETED	2019-03-28	NCT02514174
Catalysis SL	—	—	COMPLETED	2019-03-15	NCT03550482
Bristol-Myers Squibb	nab-paclitaxel	—	COMPLETED	2017-07-14	NCT02151149
Boehringer Ingelheim	Afatinib	—	COMPLETED	2017-05-17	NCT02208843
Roche	erlotinib [Tarceva]	—	COMPLETED	2015-01	NCT01609543
Roche	Erlotinib	—	COMPLETED	2014-12	NCT02000531
Roche	erlotinib [Tarceva]	—	COMPLETED	2013-11	NCT01287754
Betta Pharmaceuticals Co., Ltd.	Icotinib	—	COMPLETED	2013-10	NCT01465243
Roche	Erlotinib	—	COMPLETED	2013-09	NCT01230710
Eli Lilly	Pemetrexed	Dihydrofolate reductase/Folylpolyglutamate Synthetase/Glycinamide Ribonucleotide Formyltransferase/Thymidylate Synthase	COMPLETED	2011-03	NCT01020786
AstraZeneca	Gefitinib	Kinase Inhibitor [EPC]	COMPLETED	2011-01	NCT00770588
AstraZeneca	—	—	COMPLETED	2010-04	NCT01000740
Roche	erlotinib [Tarceva]	—	COMPLETED	2009-11	NCT01066884
Galvanize Therapeutics, Inc.	Nivolumab plus Platinum Doublet Chemotherapy	—	TERMINATED	2024-02-08	NCT05583188
Hikma Pharmaceuticals LLC	Pemetrexed	Dihydrofolate reductase/Folylpolyglutamate Synthetase/Glycinamide Ribonucleotide Formyltransferase/Thymidylate Synthase	TERMINATED	2018-11-14	NCT03460678
Boehringer Ingelheim	Afatinib	—	TERMINATED	2016-08-26	NCT02695290
Betta Pharmaceuticals Co., Ltd.	Icotinib	—	SUSPENDED	2015-12	NCT01720901

Showing 100 of 388 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
mAbxience Research S.L.	MB12 (Proposed Pembrolizumab Biosimilar)	—	RECRUITING	2026-06	NCT06687369
Hansoh BioMedical R&D Company	HS-20117	—	RECRUITING	2026-06-01	NCT06417008
Shenyang Sunshine Pharmaceutical Co., LTD.	SSGJ-707	—	RECRUITING	2026-07-30	NCT06980272
AstraZeneca	Dato-DXd	—	RECRUITING	2026-09-30	NCT06417814
Beijing Pearl Biotechnology Limited Liability Company	PLB1001	—	RECRUITING	2026-09-30	NCT05989542
Allist Pharmaceuticals, Inc.	JAB-21822	—	RECRUITING	2026-09-30	NCT06416410
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	D-1553 Tablet	—	RECRUITING	2026-10	NCT06300177
Akeso	Cadonilimab (AK104)	—	RECRUITING	2026-10-28	NCT06617416
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	SKB264	—	RECRUITING	2026-12	NCT06711900
Qilu Pharmaceutical Co., Ltd.	QL2107	—	RECRUITING	2026-12	NCT06754644
Mabscale, LLC	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	RECRUITING	2026-12	NCT05654454
Celltrion	CT-P51	—	RECRUITING	2027-02	NCT06939595
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	SKB264	—	RECRUITING	2027-05	NCT06670196
Akeso	Ivonescimab, docetaxel	—	RECRUITING	2027-05	NCT06928389
InSightec	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	RECRUITING	2027-06-01	NCT05317858
Amgen	Sotorasib	KRAS G12C	RECRUITING	2027-06-30	NCT05920356
Changchun GeneScience Pharmaceutical Co., Ltd.	Nano-crystalline Megestrol Acetate Oral Suspension	—	RECRUITING	2027-06-30	NCT07150663
OncoC4, Inc.	Gotistobart	—	RECRUITING	2027-08-31	NCT05671510
Qilu Pharmaceutical Co., Ltd.	QL1706 injection	—	RECRUITING	2027-08-31	NCT05487391
Bayer	Sevabertinib	EGFR/ERBB2	RECRUITING	2027-10-28	NCT06452277
Eli Lilly	LY3537982	—	RECRUITING	2027-11	NCT06119581
Allist Pharmaceuticals, Inc.	Firmonertinib Mesilate Tablets	—	RECRUITING	2027-12	NCT06956001
Sichuan Baili Pharmaceutical Co., Ltd.	BL-M07D1	—	RECRUITING	2027-12	NCT07178795
Revolution Medicines, Inc.	daraxonrasib	—	RECRUITING	2027-12-01	NCT06881784
OSE Immunotherapeutics	OSE2101	—	RECRUITING	2027-12-15	NCT06472245
3D Medicines (Sichuan) Co., Ltd.	Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection	—	RECRUITING	2027-12-30	NCT06123754
RemeGen Co., Ltd.	RC148 plus Carboplatin and Paclitaxel	—	RECRUITING	2027-12-31	NCT07416474
Merck	Sacituzumab tirumotecan	—	RECRUITING	2028-01-25	NCT06170788
Nanjing Sanhome Pharmaceutical, Co., Ltd.	SH-1028 tablets	—	RECRUITING	2028-02-01	NCT06080776
Shanghai JMT-Bio Inc.	Glumetinib	—	RECRUITING	2028-02-15	NCT06829459
Daiichi Sankyo	Datopotamab Deruxtecan	—	RECRUITING	2028-02-29	NCT05215340
AbbVie	Telisotuzumab Vedotin	—	RECRUITING	2028-03	NCT04928846
Pfizer	PF-08046054	—	RECRUITING	2028-03-10	NCT07144280
AstraZeneca	Osimertinib	—	RECRUITING	2028-03-21	NCT06350097
Summit Therapeutics	Ivonescimab Injection	—	RECRUITING	2028-04	NCT06767514
Betta Pharmaceuticals Co., Ltd.	Befotertinib + Icotinib placebo	—	RECRUITING	2028-04-30	NCT06041776
AstraZeneca	Durvalumab	Programmed Death Ligand-1 Blocker [EPC]	RECRUITING	2028-07-12	NCT05211895
Merck	Sacituzumab tirumotecan	—	RECRUITING	2028-08-17	NCT06305754
InxMed (Shanghai) Co., Ltd.	IN10018 in combination with D-1553	—	RECRUITING	2028-09	NCT07174908
Pfizer	Sigvotatug Vedotin	—	RECRUITING	2028-09-05	NCT06758401
Bristol-Myers Squibb	Iza-bren	—	RECRUITING	2028-09-15	NCT07100080
NovoCure GmbH	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	RECRUITING	2028-10	NCT06216301
Allist Pharmaceuticals, Inc.	Firmonertinib	—	RECRUITING	2028-10-31	NCT07010419
Roche	Divarasib	—	RECRUITING	2028-11-30	NCT06793215
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	RECRUITING	2028-12	NCT06838273
Summit Therapeutics	Ivonescimab Injection	—	RECRUITING	2028-12-31	NCT05899608
Nuvation Bio Inc.	Taletrectinib	—	RECRUITING	2029-01	NCT06564324
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	RECRUITING	2029-01-12	NCT06422143
AstraZeneca	Datopotamab deruxtecan (Dato-DXd)	—	RECRUITING	2029-01-29	NCT07291037
Beijing Pearl Biotechnology Limited Liability Company	Vebreltinib combined with platinum-based doublet chemotherapy.	—	RECRUITING	2029-02	NCT06930794
BioNTech SE	Pumitamig	—	RECRUITING	2029-02	NCT06712316
AstraZeneca	Rilvegostomig	—	RECRUITING	2029-02-05	NCT06692738
Merck	Calderasib	—	RECRUITING	2029-02-19	NCT06345729
Pfizer	PF-08634404	—	RECRUITING	2029-02-27	NCT07222566
Eli Lilly	Olomorasib	—	RECRUITING	2029-05	NCT06890598
AstraZeneca	Rilvegostomig	—	RECRUITING	2029-05-10	NCT06627647
Dizal (Jiangsu) Pharmaceutical Co., Ltd.	sunvozertinib	—	RECRUITING	2029-09	NCT07182682
Mirati Therapeutics Inc.	Adagrasib	KRAS G12C	RECRUITING	2029-09-07	NCT06875310
Nuvalent Inc.	Neladalkib (NVL-655)	—	RECRUITING	2029-12	NCT06765109
Merck	Calderasib	—	RECRUITING	2029-12-07	NCT07190248
AstraZeneca	Datopotamab Deruxtecan	—	RECRUITING	2029-12-28	NCT06357533
Daiichi Sankyo	Trastuzumab Deruxtecan	—	RECRUITING	2030-03-05	NCT06899126
Merck	Intismeran autogene	—	RECRUITING	2030-06-25	NCT06077760
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	RECRUITING	2030-07-30	NCT06561386
Nuvation Bio Inc.	Taletrectinib	—	RECRUITING	2030-08-30	NCT07154706
AbbVie	Telisotuzumab Adizutecan	—	RECRUITING	2030-09	NCT07155187
Bristol-Myers Squibb	Pumitamig	—	RECRUITING	2030-09-18	NCT07361497
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-8068，adebelizumab and platinum-based chemotherapy	—	RECRUITING	2030-12	NCT07170995
Bristol-Myers Squibb	BMS-986504	—	RECRUITING	2031-08-12	NCT07063745
AbbVie	Livmoniplimab	—	RECRUITING	2031-10	NCT06236438
Bristol-Myers Squibb	Pumitamig	—	RECRUITING	2031-10-14	NCT07361510
AbbVie	Standard of Care	—	RECRUITING	2031-12	NCT07005102
Boehringer Ingelheim	Zongertinib	Kinase Inhibitor [EPC]	RECRUITING	2032-02-26	NCT07195695
Mirati Therapeutics Inc.	Adagrasib	KRAS G12C	RECRUITING	2032-06-09	NCT04613596
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-A2009 ; Aumolertinib	—	RECRUITING	2032-11	NCT07183189
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	RECRUITING	2033-05-16	NCT06623422
Merck	Sacituzumab tirumotecan	—	RECRUITING	2034-02-21	NCT06312137
Merck	Intismeran	—	RECRUITING	2034-08-22	NCT07513376
Eikon Therapeutics	EIK1001	—	RECRUITING	2035-12-31	NCT07365319
Merck	Calderasib	—	RECRUITING	2039-10-26	NCT07431827
Jiangsu HengRui Medicine Co., Ltd.	SHR-A1811	—	RECRUITING	2026-02	NCT06430437
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules	—	RECRUITING	2025-08	NCT05922345
Betta Pharmaceuticals Co., Ltd.	Ensartinib	—	RECRUITING	2025-06-01	NCT05341583
TYK Medicines, Inc	TY-9591	—	RECRUITING	2025-05	NCT05382728
Laboratorio Elea Phoenix S.A.	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	RECRUITING	2024-08	NCT05668650
Jiangsu Hansoh Pharmaceutical Co., Ltd.	Almonertinib	—	RECRUITING	2024-07-15	NCT04951635
AstraZeneca	Durvalumab	Programmed Death Ligand-1 Blocker [EPC]	ACTIVE NOT RECRUITING	2026-06-30	NCT05221840
Merck	pembrolizumab/vibostolimab	—	ACTIVE NOT RECRUITING	2026-08-19	NCT05298423
Novartis	JDQ443	—	ACTIVE NOT RECRUITING	2026-08-25	NCT05132075
Hutchison Medipharma Limited	Savolitinib	—	ACTIVE NOT RECRUITING	2026-08-30	NCT05009836
Pfizer	Avelumab	Programmed Death Ligand-1 Blocker [EPC]	ACTIVE NOT RECRUITING	2026-09-30	NCT05059522
Innovent Biologics (Suzhou) Co. Ltd.	Pemetrexed	Dihydrofolate reductase/Folylpolyglutamate Synthetase/Glycinamide Ribonucleotide Formyltransferase/Thymidylate Synthase	ACTIVE NOT RECRUITING	2026-09-30	NCT05116462
Takeda	TAK-788	—	ACTIVE NOT RECRUITING	2026-10-31	NCT04129502
Roche	Alectinib	—	ACTIVE NOT RECRUITING	2026-10-31	NCT03178552
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	SKB264	—	ACTIVE NOT RECRUITING	2026-11	NCT06448312
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	Alectinib - Usual	—	ACTIVE NOT RECRUITING	2026-11-18	NCT05987956
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	ACTIVE NOT RECRUITING	2026-12	NCT06382129
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-A2009 monotherapy	—	ACTIVE NOT RECRUITING	2026-12	NCT06671379
Amgen	ABP 234	—	ACTIVE NOT RECRUITING	2026-12-14	NCT06430866
Merck	Sacituzumab Govitecan	—	ACTIVE NOT RECRUITING	2027-01-12	NCT05609968

Showing 100 of 800 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
RemeGen Co., Ltd.	RC108	—	RECRUITING	2026-05-31	NCT06962865
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	TQB2102 for injection	—	RECRUITING	2026-06	NCT06496490
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQB2450 injection + Chemotherapy	—	RECRUITING	2026-06	NCT05913089
Portage Biotech	TT-10	—	RECRUITING	2026-06-01	NCT04969315
Aulos Bioscience, Inc.	AU-007	—	RECRUITING	2026-06-12	NCT05267626
Medicenna Therapeutics, Inc.	MDNA11	—	RECRUITING	2026-06-30	NCT05086692
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-8068；Adebrelimab	—	RECRUITING	2026-06-30	NCT05416775
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	RECRUITING	2026-07	NCT06475300
CJ Bioscience, Inc.	CJRB-101	—	RECRUITING	2026-07	NCT05877430
Shanghai Henlius Biotech	HLX43 DOSE 1	—	RECRUITING	2026-07-10	NCT07269782
InxMed (Shanghai) Co., Ltd.	IN10018	—	RECRUITING	2026-07-31	NCT05994131
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	SKB264	—	RECRUITING	2026-08	NCT05351788
Integro Theranostics	LS301-IT 0.1 mg/kg	—	RECRUITING	2026-08	NCT07276789
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	RECRUITING	2026-08	NCT06498986
CrystalGenomics, Inc.	Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin	—	RECRUITING	2026-08	NCT05841472
OncoResponse, Inc.	OR502	—	RECRUITING	2026-08-01	NCT06090266
PMV Pharmaceuticals, Inc	rezatapopt	—	RECRUITING	2026-08-15	NCT04585750
MediLink Therapeutics (Suzhou) Co., Ltd.	YL202	—	RECRUITING	2026-08-31	NCT07202364
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-1826；Adebrelimab；SHR-8068；Bevacizumab	—	RECRUITING	2026-08-31	NCT06844474
MediLink Therapeutics (Suzhou) Co., Ltd.	YL202 for injection; Toripalimab injection	—	RECRUITING	2026-09-01	NCT07169994
ImmVira Pharma Co. Ltd	T3011	—	RECRUITING	2026-09-22	NCT04370587
J Ints Bio	JIN-A02	—	RECRUITING	2026-09-30	NCT05394831
Shanghai Hengrui Pharmaceutical Co., Ltd.	SHR-A2102 for Injection	—	RECRUITING	2026-10	NCT06512051
Shanghai Hengrui Pharmaceutical Co., Ltd.	SHR-A2102	—	RECRUITING	2026-10	NCT07229729
Inhatarget Therapeutics	CIS-DPI	—	RECRUITING	2026-10-01	NCT06896890
Shanghai Henlius Biotech	HLX43 dose 1	—	RECRUITING	2026-10-30	NCT06848699
MediLink Therapeutics (Suzhou) Co., Ltd.	YL202 should be intravenously infused	—	RECRUITING	2026-11	NCT06107686
Anbogen Therapeutics, Inc.	ABT-101	—	RECRUITING	2026-11	NCT05532696
ToLymph Inc.	SMS001	—	RECRUITING	2026-11-18	NCT06693336
Roche	Alectinib	—	RECRUITING	2026-11-30	NCT04302025
Innovent Biologics (Suzhou) Co. Ltd.	Pemetrexed	Dihydrofolate reductase/Folylpolyglutamate Synthetase/Glycinamide Ribonucleotide Formyltransferase/Thymidylate Synthase	RECRUITING	2026-11-30	NCT07122687
Lantern Pharma Inc.	LP-300	—	RECRUITING	2026-12	NCT05456256
Jiangsu HengRui Medicine Co., Ltd.	SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316	—	RECRUITING	2026-12	NCT05482568
3D Medicines (Sichuan) Co., Ltd.	Lenvatinib + Envafolimab	—	RECRUITING	2026-12	NCT05024214
Ellipses Pharma	EP0031	—	RECRUITING	2026-12	NCT05443126
One-carbon Therapeutics AB	TH9619	—	RECRUITING	2026-12	NCT07151040
Dizal Pharmaceuticals	DZD9008+AZD4205	—	RECRUITING	2026-12	NCT06295432
Eikon Therapeutics	EIK1001	—	RECRUITING	2026-12	NCT06246110
Sichuan Baili Pharmaceutical Co., Ltd.	SI-B001	—	RECRUITING	2026-12	NCT05949606
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	RECRUITING	2026-12	NCT05956587
Akeso	AK129(dose 1)	—	RECRUITING	2026-12	NCT06943820
AP Biosciences Inc.	AP203	—	RECRUITING	2026-12	NCT05473156
GV20 Therapeutics	GV20-0251	—	RECRUITING	2026-12-15	NCT05669430
HC Biopharma Inc.	HC010	—	RECRUITING	2026-12-30	NCT07169552
Jazz Pharmaceuticals	Zanidatamab	—	RECRUITING	2026-12-31	NCT06695845
MediLink Therapeutics (Suzhou) Co., Ltd.	YL201	—	RECRUITING	2027-01	NCT07208773
Genelux Corporation	Olvimulogene nanivacirepvec	—	RECRUITING	2027-02	NCT06463665
GI Innovation, Inc.	GI-108	—	RECRUITING	2027-02	NCT07172802
Beijing Biotech	Dual-target CAR-NK cells	—	RECRUITING	2027-02-14	NCT07467863
Neonc Technologies, Inc.	NEO212 Oral Capsule	—	RECRUITING	2027-02-28	NCT06047379
Elpiscience (Suzhou) Biopharma, Ltd.	ES102	—	RECRUITING	2027-02-28	NCT06623136
Tango Therapeutics, Inc.	TNG456	—	RECRUITING	2027-03-31	NCT06810544
Suzhou Zelgen Biopharmaceuticals Co.,Ltd	ZG005 for Injection	—	RECRUITING	2027-04	NCT06903377
Eli Lilly	LY3537982	—	RECRUITING	2027-04	NCT04956640
Regeneron	Cemiplimab	—	RECRUITING	2027-05-20	NCT06465329
Jiangsu Alphamab Biopharmaceuticals Co., Ltd	KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)	—	RECRUITING	2027-05-29	NCT05420220
Revolution Medicines, Inc.	RMC-6236	—	RECRUITING	2027-05-31	NCT05379985
Tango Therapeutics, Inc.	TNG462	—	RECRUITING	2027-06	NCT06922591
Revolution Medicines, Inc.	RMC-6291	—	RECRUITING	2027-06	NCT06162221
ITM Oncologics GmbH	[68Ga]Ga-DPI-4452	—	RECRUITING	2027-06	NCT05706129
Dizal Pharmaceuticals	DZD6008	—	RECRUITING	2027-06	NCT07070440
Wayshine Biopharm, Inc.	WSD0922-FU	—	RECRUITING	2027-06-30	NCT06631989
Genmab	Rina-S	—	RECRUITING	2027-07	NCT05579366
Hummingbird Bioscience	ENV-501	—	RECRUITING	2027-07	NCT06956690
GV20 Therapeutics	GV20-0251	—	RECRUITING	2027-07-16	NCT07070518
AstraZeneca	Volrustomig	—	RECRUITING	2027-07-30	NCT06448754
Henan Genuine Biotech Co., Ltd.	GEN-725 tablets + Dositinib mesylate tablets	—	RECRUITING	2027-07-31	NCT07362940
Johnson & Johnson	Amivantamab	—	RECRUITING	2027-08-17	NCT05498428
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Sacituzumab Tirumotecan	—	RECRUITING	2027-08-31	NCT07329322
STCube, Inc.	Nelmastobart and Docetaxel	—	RECRUITING	2027-08-31	NCT07306624
Daiichi Sankyo	HER3-DXd	—	RECRUITING	2027-09-01	NCT06172478
AstraZeneca	AZD8205	—	RECRUITING	2027-09-29	NCT05123482
Wayshine Biopharm, Inc.	WSD0922-FU Tablets, Dose level A	—	RECRUITING	2027-09-30	NCT06868485
Frontier Medicines Corporation	FMC-376	—	RECRUITING	2027-10	NCT06244771
Pierre Fabre Medicament	STX-241	—	RECRUITING	2027-11-20	NCT06567015
Genmab	Rina-S	—	RECRUITING	2027-11-22	NCT07288177
Teligene US	Sutetinib Maleate Capsule	—	RECRUITING	2027-12	NCT05168566
Teligene US	Sutetinib Maleate Capsule	—	RECRUITING	2027-12	NCT06010329
Radiopharm Theranostics, Ltd	177Lu-BetaBart	—	RECRUITING	2027-12	NCT07189871
Sichuan Baili Pharmaceutical Co., Ltd.	BL-M07D1	—	RECRUITING	2027-12	NCT07264816
Tubulis GmbH	TUB-040	—	RECRUITING	2027-12	NCT06303505
VM Oncology, LLC	VMD-928 100 mg Tablet	—	RECRUITING	2027-12	NCT03556228
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-1826	—	RECRUITING	2027-12	NCT06754930
Phanes Therapeutics	Mavrostobart (PT199)	—	RECRUITING	2027-12	NCT05431270
Hummingbird Bioscience	HMBD-001	—	RECRUITING	2027-12-01	NCT05910827
EMD Serono Research & Development Institute, Inc.	M9140	—	RECRUITING	2027-12-23	NCT06710132
Precision Biotech Taiwan Corp.	donor-derived NK cell infusion	—	RECRUITING	2027-12-30	NCT04616209
Abbisko Therapeutics Co, Ltd	ABSK043 in combination with Firmonertinib	—	RECRUITING	2027-12-30	NCT06668103
Suzhou BlueHorse Therapeutics Co., Ltd.	LM103 TILs Injection	—	RECRUITING	2027-12-31	NCT07444437
7 Hills Pharma, LLC	Alintegimod	—	RECRUITING	2027-12-31	NCT06362369
Henan Genuine Biotech Co., Ltd.	Dositinib mesylate tablets	—	RECRUITING	2027-12-31	NCT07231068
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	GTAEXS617	—	RECRUITING	2028-01	NCT05985655
Auricula Biosciences Inc.	WEF-001	—	RECRUITING	2028-01	NCT07148128
Jacobio Pharmaceuticals Co., Ltd.	JAB-8263	—	RECRUITING	2028-01	NCT04686682
Precision Biologics, Inc	NEO-201 in combination with pembrolizumab	—	RECRUITING	2028-01-15	NCT03476681
AbbVie	Telisotuzumab Vedotin	—	RECRUITING	2028-02	NCT06568939
Yuhan Corporation	YH42946	—	RECRUITING	2028-03-15	NCT06616766
Daiichi Sankyo	valemetostat tosylate	—	RECRUITING	2028-03-30	NCT06644768
Shanghai Henlius Biotech	HLX43 DOSE 1 (2.0 mg/kg)	—	RECRUITING	2028-04-20	NCT06907615
Betta Pharmaceuticals Co., Ltd.	MCLA-129	—	RECRUITING	2028-04-30	NCT04930432

Showing 100 of 554 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Qilu Pharmaceutical Co., Ltd.	QLC1101	—	RECRUITING	2026-05-31	NCT06403735
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.	BC008-1A 900mg	—	RECRUITING	2026-06	NCT06773507
A&G Pharmaceutical Inc.	AG-01 Compound	—	RECRUITING	2026-06	NCT05627960
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.	DM001	—	RECRUITING	2026-08-13	NCT06475937
TORL Biotherapeutics, LLC	TORL-1-23	—	RECRUITING	2026-08-31	NCT05103683
Nurix Therapeutics, Inc.	NX-1607	—	RECRUITING	2026-08-31	NCT05107674
IDEAYA Biosciences	IDE-161	—	RECRUITING	2026-10	NCT05787587
Sichuan Baili Pharmaceutical Co., Ltd.	GNC-077	—	RECRUITING	2026-10	NCT06612840
Doma Biopharmaceutical（Suzhou）Co., Ltd.	DM005	—	RECRUITING	2026-10	NCT06515990
Exelixis	XB010	—	RECRUITING	2026-11-23	NCT06545331
ORIC Pharmaceuticals	ORIC-114 Dose 1 + amivantamab	—	RECRUITING	2026-12	NCT06816992
Compass Therapeutics	CTX-8371	—	RECRUITING	2026-12	NCT06150664
Zumutor Biologics Inc.	ZM008	—	RECRUITING	2026-12	NCT06451497
Allist Pharmaceuticals, Inc.	AST2303 Tablets(ABK3376 Tablets) ，25mg	—	RECRUITING	2026-12	NCT06955988
Nuvectis Pharma, Inc.	NXP900	—	RECRUITING	2026-12	NCT07315113
NextCure, Inc.	LNCB74	—	RECRUITING	2026-12	NCT06774963
Betta Pharmaceuticals Co., Ltd.	BPI-371153	—	RECRUITING	2026-12	NCT05341557
SystImmune Inc.	BL-B01D1	—	RECRUITING	2026-12-31	NCT05983432
Chongqing Precision Biotech Co., Ltd	CEA-targeted CAR-T cells	—	RECRUITING	2026-12-31	NCT06043466
Orano Med LLC	²¹²Pb-DOTAM-GRPR1	—	RECRUITING	2027-01	NCT05283330
Kura Oncology, Inc.	Darlifarnib	—	RECRUITING	2027-01	NCT06026410
Solve Therapeutics	SLV-154	—	RECRUITING	2027-01	NCT06771219
Eli Lilly	LY4170156	—	RECRUITING	2027-02	NCT06400472
Memgen, Inc.	MEM-288 Intratumoral Injection	—	RECRUITING	2027-02	NCT05076760
Shenzhen TargetRx Co., Ltd.	TGRX-1942	—	RECRUITING	2027-02	NCT06484816
Bio-Thera Solutions	BAT3306	—	RECRUITING	2027-02-28	NCT07180862
Nuvectis Pharma, Inc.	NXP900	—	RECRUITING	2027-03	NCT05873686
Abbisko Therapeutics Co, Ltd	ABSK112	—	RECRUITING	2027-03	NCT06225804
Ankyra Therapeutics, Inc	tolododekin alfa	—	RECRUITING	2027-04	NCT06171750
Mersana Therapeutics	XMT-2056	—	RECRUITING	2027-04	NCT05514717
Johnson & Johnson Enterprise Innovation Inc.	JNJ-86974680	—	RECRUITING	2027-04-14	NCT06116786
Valo Therapeutics Oy	PeptiCRAd-1	—	RECRUITING	2027-04-30	NCT05492682
Shanghai Henlius Biotech	HLX17	—	RECRUITING	2027-04-30	NCT07160335
Eli Lilly	LY4052031	—	RECRUITING	2027-05	NCT06465069
Sairopa B.V.	ADU-1805	—	RECRUITING	2027-05	NCT05856981
Normunity AccelCo, Inc.	NRM-823	—	RECRUITING	2027-05-30	NCT07182149
Olema Pharmaceuticals, Inc.	OP-3136	—	RECRUITING	2027-05-30	NCT06784193
ALX Oncology Inc.	ALX2004	—	RECRUITING	2027-06	NCT07085091
Cytocraft Biopharmaceutical Co., Ltd.	SDT-M001 injection	—	RECRUITING	2027-06-26	NCT07096882
AstraZeneca	T-DXd	—	RECRUITING	2027-06-30	NCT04686305
Ankyra Therapeutics, Inc	tolododekin alfa	—	RECRUITING	2027-06-30	NCT07027514
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.	Drug: IBI3028	—	RECRUITING	2027-06-30	NCT07589205
AbbVie	Azirkitug	—	RECRUITING	2027-07	NCT05005403
Dren Bio	DR-0202	—	RECRUITING	2027-07	NCT06999187
IDEAYA Biosciences	IDE034	—	RECRUITING	2027-07-30	NCT07503808
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	BBO-11818	—	RECRUITING	2027-08	NCT06917079
Pfizer	PF-07799544	—	RECRUITING	2027-08-09	NCT05538130
AstraZeneca	NT-112: Autologous, engineered T Cells targeting KRAS G12D	—	RECRUITING	2027-08-30	NCT06218914
Zymeworks BC Inc.	ZW251	—	RECRUITING	2027-09	NCT07164313
DeuterOncology	DO-2	—	RECRUITING	2027-09	NCT05752552
Dizal Pharmaceuticals	DZD6008	—	RECRUITING	2027-09	NCT06905197
KaliVir Immunotherapeutics	VET3-TGI	—	RECRUITING	2027-09-30	NCT06444815
Incendia Therapeutics	PRTH-101	—	RECRUITING	2027-09-30	NCT05753722
Eli Lilly	LY4050784	—	RECRUITING	2027-10	NCT06561685
LG Chem	Phase 1a: LB-LR1109	—	RECRUITING	2027-11	NCT06332755
Aktis Oncology, Inc.	[225Ac]Ac-AKY-1189 (therapeutic)	—	RECRUITING	2027-12	NCT07020117
Iambic Therapeutics, Inc	IAM1363	—	RECRUITING	2027-12	NCT06253871
Aptamer Sciences, Inc.	AST-201	—	RECRUITING	2027-12	NCT06687941
Sutro Biopharma, Inc.	STRO-004	—	RECRUITING	2027-12	NCT07227168
Jiangsu Simcere Pharmaceutical Co., Ltd.	SIM0610 for Injection	—	RECRUITING	2027-12	NCT07348211
Oscotec Inc.	OCT-598	—	RECRUITING	2027-12	NCT07358806
Sichuan Baili Pharmaceutical Co., Ltd.	BL-M24D1	—	RECRUITING	2027-12	NCT07232420
Sichuan Baili Pharmaceutical Co., Ltd.	BL-M09D1	—	RECRUITING	2027-12	NCT07056556
Ascentage Pharma Group Inc.	APG-2449	—	RECRUITING	2027-12	NCT03917043
Bristol-Myers Squibb	MRTX1719	—	RECRUITING	2027-12-10	NCT05245500
Fate Therapeutics	FT836	—	RECRUITING	2028-01	NCT07216105
Seagen, a wholly owned subsidiary of Pfizer	PF-08046054	—	RECRUITING	2028-01-05	NCT05208762
Pfizer	PF-07934040	—	RECRUITING	2028-01-19	NCT06447662
Avistone Biotechnology Co., Ltd.	PLB1004	—	RECRUITING	2028-02-09	NCT06046495
Revolution Medicines, Inc.	RMC-5127	—	RECRUITING	2028-04	NCT07349537
IDEAYA Biosciences	IDE892	—	RECRUITING	2028-04-30	NCT07277413
Cogent Biosciences, Inc.	CGT4255	—	RECRUITING	2028-05	NCT07361562
MacroGenics	MGC026 Dose Escalation	—	RECRUITING	2028-05	NCT06242470
AstraZeneca	FPI-2053	—	RECRUITING	2028-05-12	NCT06147037
BeOne Medicines	BGB-B2033	—	RECRUITING	2028-05-30	NCT06427941
Jiangsu Alphamab Biopharmaceuticals Co., Ltd	JSKN016	—	RECRUITING	2028-06-30	NCT06868732
Epkin	OKN4395	—	RECRUITING	2028-07	NCT06789172
Pfizer	PF-08046876	—	RECRUITING	2028-07-08	NCT07090499
Roche	Enzelkitug	—	RECRUITING	2028-07-31	NCT05581004
PAQ Therapeutics, Inc.	PT0511	—	RECRUITING	2028-10-18	NCT07300150
Amgen	Anvumetostat	—	RECRUITING	2028-10-27	NCT06333951
Nested Therapeutics, Inc	NST-628	—	RECRUITING	2028-11	NCT06326411
BeOne Medicines	BGB-43395	—	RECRUITING	2028-11	NCT06120283
Bristol-Myers Squibb	BMS-986463	—	RECRUITING	2028-12-19	NCT06476808
Eli Lilly	LY3962673	—	RECRUITING	2029-03	NCT06586515
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	EXS74539	—	RECRUITING	2029-03	NCT07517198
Kyowa Kirin Co., Ltd.	KK2269	—	RECRUITING	2029-03	NCT06266299
Alterome Therapeutics, Inc.	ALTA3263	—	RECRUITING	2029-05	NCT06835569
Novartis	68Ga-NNS309	—	RECRUITING	2029-05-09	NCT07261631
EpiBiologics	EPI-326	—	RECRUITING	2029-07	NCT07462377
Ono Pharmaceutical Co., Ltd.	ONO-7428	—	RECRUITING	2029-07	NCT06816108
AstraZeneca	Autologous, engineered T Cells targeting TP53 R175H	—	RECRUITING	2029-07-31	NCT05877599
Seagen, a wholly owned subsidiary of Pfizer	PF-08046050	—	RECRUITING	2029-09-12	NCT06131840
Astellas Pharma Global Development, Inc.	gilteritinib	—	RECRUITING	2029-12-31	NCT07140016
BioNTech SE	BNT116	—	RECRUITING	2030-02	NCT05142189
Exelixis	Zanzalintinib	—	RECRUITING	2030-06-28	NCT05176483
Eli Lilly	LY4175408	—	RECRUITING	2030-07	NCT07046923
AbbVie	Lenvatinib	—	RECRUITING	2030-09	NCT06858813
Novartis	[68Ga]Ga-NNS309	—	RECRUITING	2031-01-15	NCT06562192
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	BBO-8520	—	RECRUITING	2031-04	NCT06343402

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Non-Small Cell Lung Cancer

HER2 (22) VEGF (17) EGFR (16) RET (14) ROS1 (11) PD-1 (11)

Novel Drugs by Company (New molecular entities)

Novartis 3 drugs

Bristol-Myers Squibb 2 drugs

Eli Lilly 2 drugs

Roche 2 drugs

ALECTINIB HYDROCHLORIDE

NDA 2015

Boehringer Ingelheim 2 drugs

AstraZeneca 2 drugs

Merck 2 drugs

Pfizer 2 drugs

AVYXA HOLDINGS 1 drug

AXTLE

PEMETREXED DIPOTASSIUM

Takeda 1 drug

+11 more companies

Reformulations (14 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.